ArticleThe Journal of antimicrobial chemotherapy2023

Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir.

Ana González-Cordón et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.